- 1 Antibiotic prescriptions in children with COVID-19 and Multisystem Inflammatory
- 2 Syndrome: a multinational experience in 990 cases from Latin America
- 3 Adriana Yock-Corrales, MD¹; Jacopo Lenzi, PhD²; Rolando Ulloa-Gutiérrez, MD³; Jessica Gómez-
- 4 Vargas, MD¹; Antúnez-Montes Omar Yassef MD⁴; Jorge Alberto Rios Aida MD⁵; Olguita del
- 5 Aguila, MD⁶; Erick Arteaga-Menchaca MD⁷; Francisco Campos MD⁸; Fadia Uribe MD⁸; Andrea
- 6 Parra Buitrago, MD^{9,10}; Lina Maria Betancur Londoño, MD⁹; Martin Brizuela MD¹¹; Danilo
- 7 Buonsenso MD^{12,13,14}
- 9 ¹ Pediatric Emergency Department, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS,
- 10 San José, Costa Rica.

- ² Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of
- 12 Bologna, Bologna, Italy
- ³Infectious Disease Department. Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS,
- 14 San José, Costa Rica.
- ⁴Departamento de Docencia e Investigación, Instituto Latinoamericano de Ecografía en Medicina
- 16 (ILEM)., Ciudad de Mexico, Mexico
- ⁵ CLÍNICA JAS MÉDICA, Lima, Perù
- ⁶ Unidad de Infectología Pediátrica del Hospital Nacional Edgardo Rebagliati Martins-Lima-Perú.
- ⁷Hospital General Regional 200 IMSS, Mexico
- 20 ⁸Hospital Madre Niño San Bartolome, Lima, Peru
- ⁹Hospital Pablo Tobon Uribe Medellin, Colombia
- 22 ¹⁰Fundacion Neumologica Colombiana, Bogotà, Colombia
- ¹¹Pediatric Infectious Disease, Hospital isidoro Iriarte, Quilmes, Buenos Aires, Argentina
- 24 ¹² Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario
- 25 A. Gemelli, Rome, Italy
- 26 ¹³ Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie,
- 27 Università Cattolica del Sacro Cuore, Rome, Italy

- ¹⁴Global Health Research Institute, Istituto di Igiene, Università Cattolica del Sacro Cuore, Roma,
- 29 Italia

- 30 Email addresses:
- 31 Adriana Yock-Corrales, adriyock@gmail.com
- 32 Jacopo Lenzi, jacopo.lenzi2@unibo.it
- 33 Rolando Ulloa-Gutiérrez, rolandoug@gmail.com
- 34 Jessica Gómez-Vargas, jemagova@gmail.com
- 35 Antúnez-Montes Omar Yassef, antunezyassef@gmail.com
- 36 Jorge Alberto Rios Aida, jriosaida@gmail.com
- 37 Olguita del Aguila, odaguila@hotmail.com
- 38 Erick Arteaga-Menchaca, docarteaga@hotmail.com
- 39 Francisco Campos, francisco.e.campos@gmail.com
- 40 Fadia Uribe, kafaur87@hotmail.com
- 41 Andrea Parra Buitrago, aparra@neumologica.org
- 42 Lina Maria Betancur Londoño, lina_b16@yahoo.com
- 43 Martin Brizuela, martin.brizuela1984@gmail.com
- 44 Danilo Buonsenso, danilobuonsenso@gmail.com

Abstract

46

47

Background

- 48 To date, there are no comprehensive data on antibiotic use in children with COVID-19 and
- 49 Multisystem Inflammatory Syndrome (MIS-C).
- 50 Methods
- Multicenter cohort study from 5 Latin American countries. Children 17 years of age or younger
- 52 with microbiologically confirmed SARS-CoV-2 infection or fulfilling MIS-C definition were
- 53 included. Antibiotic prescriptions were collected and factors associated with their use were
- 54 calculated.

55 Findings

- 56 990 children were included, with a median age of 3 years (interquartile range 1–9). Of these, 69
- 57 (7.0%) were diagnosed with MIS-C. The prevalence of antibiotic use was 24.5% (n = 243). MIS-C
- with (OR = 45.48) or without (OR = 10.35) cardiac involvement, provision of intensive care (OR = 10.35)
- = 9.60), need for hospital care (OR = 6.87), pneumonia and/or ARDS detected through chest X-
- 60 rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support,
- mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50)
- 62 were independently associated with increased use of antibiotics. On the contrary, lower
- 63 respiratory tract infections without radiologic evidence of pneumonia/ARDS and not requiring
- respiratory support (OR = 0.34) were independently associated with decreased use of antibiotics.
- 65 There was significant variation in antibiotic use across the hospitals.

66 Conclusions

73

74

75

- Our study showed a relatively high rate of antibiotic prescriptions in children with COVID-19 and
- in particular in those with severe disease or MIS-C. Importantly, we found a significant variation in
- 69 reasons for prescriptions of antibiotics and type of chosen therapies, as well in hospital practices,
- 70 highlighting current uncertainties and lack of guidelines for the recognition of bacterial infections in
- 71 children with COVID-19. Prospective studies are needed to provide better evidence on the
- 72 recognition and management of bacterial infections in COVID-19 children.

Key Words: COVID-19; SARS-CoV-2; MIS-C; antibiotic stewardship **List of Abbreviation** COVID-19: coronavirus disease 2019 SARS-CoV-2: severe acute respiratory syndrome coronavirus-2 MIS-C: multisystem inflammatory syndrome in children What is known COVID-19 may worsen antibiotic prescription practices What this new COVID-19 and MIS-C children frequently received antibiotics There was a wide variation in antibiotic prescriptions among institutions, highlighting the lack of practicle guidelines in the use of antibiotics in children with COVID-19

100 101 *Declarations 102 **Funding:** no funds received 103 **Conflicts of interest:** nothing to declare Ethics approval: Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-104 105 06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020 106 Consent to participate: approved 107 Consent for publication: approved Availability of data and material: available upon request 108 109 Authors' contributions: DB conceptualized the study. JL performed statistical analyses. All authors 110 contributed with data collection, writing of the draft of the manuscript- All authors read and approved the 111 final version of the manuscript. 112 113 114 115

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Introduction Months after the first description of COVID-19 in China, growing evidence is raising about the impact of SARS-CoV-2 infection on the pediatric population. Several studies from China (1), Europe (2,3), United States (4) and Latin America (5) are clarifying that COVID-19 in children is typically mild, although patients with medically complex conditions or those of minority race/ethnicity deserve more attention because they may be at risk of more severe disease (4). The Multisystem Inflammatory Syndrome (MIS-C), an entity not yet fully clarified related to SARS-CoV-2, is a severe complication of the exposition to the virus, which may require Intensive Care Admission, mechanical ventilation and cardio-respiratory support, rarely leading to death (6). Because SARS-CoV-2 is a viral infection, and the resulting disease is usually mild in children, it is not expected that a child with COVID-19 would routinely receive antimicrobials. This is particularly true for the second period of the pandemic, when the non-utility of azithromycin, initially suggested as a drug with potential anti-viral properties (7), has been showed (8). The MIS-C can be an exception to this concept, since the severe and acute presentation may be similar to the toxic-shock syndrome and available consensus documents suggest empiric wide-spectrum antibiotic therapy until bacterial infections are ruled-out (9). Nevertheless, there are growing concerns about the possible negative impact of the pandemic on antimicrobial use. While this is particularly discussed for adults with COVID-19 (10), Velasco-Arnaiz et al (11) reported preliminary data suggesting that the pandemic has the potential to have a significant impact on antimicrobial use in the pediatric inpatient population. They did assess antibiotic prescriptions during and before the pandemic, but did not assess directly antibiotic use and its determinants in COVID-19 children. Since cases are constantly raising worldwide, it is expected that SARS-CoV-2 will circulate still for a long time, therefore the appropriate management of children with COVID-19 is a priority. While

the pandemic only determined a limited direct impact on children, inappropriate prescriptions have

Due to the gap in available literature, we performed a multinational study in Latin America aiming to assess the use of antibiotics in children with COVID-19 and understand the determinants of its use.

MATERIALS AND METHODS

Study Design and Participants

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

This study is part of an ongoing independent project assessing COVID-19 and MIS-C in Latin American children, already presented elsewhere (12) and with a previous published paper describing an initial group of 409 children with confirmed COVID-19 (5). For the current study, we aimed to assess determinants of antibiotic use in children with COVID-19. We implemented the previously used dataset (2, 5) including data regarding name of antibiotic used and the reason why the attending clinician decided to administer antibiotics. The remaining variables are those previously used and included age, gender, symptoms, imaging, underlying medical conditions, need for hospital and NICU/PICU admission, respiratory and cardiovascular support, other viral coinfections, drugs used to treat COVID-19, development of MIS-C and type of organ involvement, and outcome. The study was reviewed and approved by the CoviD in sOuth aMerIcaN children—study GrOup core group and approved by the Ethics Committee of the coordinating center and by each participating center (Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020). The study was conducted in accordance with the Declaration of Helsinki and its amendments. No personal or identifiable data were collected during the conduct of this study. Statistical analysis

Summary statistics for the study sample were presented as counts and percentages. The association of relevant demographic and clinical characteristics with antibiotic use was assessed using a multivariable logistic regression model; the effect size of covariates was expressed by

169

174

175

176

178

179

181

184

185

186

187

188

189

192

odds ratios (ORs) with 95% confidence intervals (CIs). The variables considered in this analysis were age, sex, medical history of immunodeficiency, immunosuppressants or chemotherapy, 170 hospital care, pyrexia, upper and lower respiratory tract infections, gastrointestinal symptoms, headache, chest X-ray abnormalities, respiratory support, administration of systemic 171 172 corticosteroids, and diagnosis of MIS-C, both with and without cardiac involvement. A set of 173 dummy variables for individual hospitals was also included in the model to adjust for the potential bias of confounding by center. All data were analyzed using the Stata 15 software (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). The significance level was set at 5% and all tests were 2-sided. 177 Role of the Funding Source The study was not supported by any funding. The corresponding authors had full access to all the data and had the final responsibility for the decision to submit for publication. 180 Dataset availability The dataset generated for this study is available upon request to the corresponding author. 182 RESULTS 183 Study population A total of 921 children (93.0%) with microbiologically confirmed COVID-19 and 69 children (7.0%) with MIS-C from Peru (n = 383, 38.7%), Costa Rica (n = 299, 30.2%), Argentina (n = 299, 30.2%)253, 25.6%), Colombia (n = 43, 4.3%) and Mexico (n = 12, 1.2%) were included in the study. The demographic and clinical characteristics of the 990 study patients are summarized in Table 1. The median age was 3 years (interquartile range: 1–9), ranging from 2 days to 17 years; 484 190 (48.9%) were female. The most common known source of transmission of the infection was a 191 parent, considered the index case in 281 (28.4%) cases. A total of 303 (30.6%) children were

admitted to hospital and 47 (4.7%) required admission to a Pediatric Intensive Care Unit (PICU).

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Fever was reported in 677 cases (68.4%); 466 (47.1%) children had symptoms suggestive of upper respiratory tract infection while 215 (21.7%) had lower respiratory tract symptoms; 301 (30.4%) had gastrointestinal symptoms. A chest radiograph was done in 285 (28.8%) patients. Of these, 92 (32.3%) had signs of COVID-19 pneumonia. Respiratory co-infections were detected in 14 (1.4%) children. We found that 118 (11.9%) individuals required respiratory support; 117 (11.8%) required low-flow oxygen support, 11 (1.1%) were started on continuous positive airway pressure and 31 (3.1%) on mechanical ventilation. A total of 29 (2.9%) patients required inotropic support. Eight children died (0.8%). Further details described in table 1. Antibiotic use in COVID-19 and MIS-C children The prevalence of antibiotic use was 24.5% (n = 243). As shown in Figure 1, sepsis was the most common reason for administering antibiotics (22.6%), followed by pneumonia (13.6%), surgical causes (11.5%) and upper or mild respiratory infections (9.5%). Information about the classes of antibiotics used was available for 153 (63.0%) patients. Among these, 86 (56.2%) received 33 (21.6%) aminoglycosides, 33 (21.6%) penicillins, 31 (20.3%) cephalosporines, antistaphylococcal drugs, 17 (11.1%) antianaerobic drugs, 14 (9.2%) macrolides, 11 (7.2%) carbapenems, and 1 (0.7%) fluoroquinolones. The percentage distribution of single and combination antibiotic therapies is illustrated in Figure 2. The rate of antibiotic prescriptions remained stable during the whole study period with an average decrease of -0.6% (95% CI -2.6%, 1.3%) from April 2020 to October 2020 (Figure 3). On multivariable analysis (Table 2), MIS-C with cardiac involvement (OR = 45.48), MIS-C with no cardiac involvement (OR = 10.35), provision of intensive care (OR = 9.60), need for hospitalization (OR = 6.87), pneumonia and/or ARDS detected through chest X-rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support, mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50) were independently

associated with increased use of antibiotics. On the contrary, lower respiratory tract infections not suggestive of pneumonia/ARDS and not requiring respiratory support (OR = 0.34) were independently associated with decreased use of antibiotics. We also found large and significant variations in antibiotic use across the hospitals.

DISCUSSION

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

In our study, the prevalence of antibiotic prescribing in children with COVID-19 and MIS-C was 24.5%. We found significant variations in classes of antibiotics used and even large differences across the hospitals. The rate of antibiotic prescriptions was significantly higher in children with MIS-C, those requiring respiratory support, those with radiologic evidence of pneumonia/ARDS and those with fever. Interestingly, younger children and those with symptoms suggestive of lower respiratory tract infections without radiologic evidence of pneumonia/ARDS and not requiring respiratory support were less frequently prescribed with antibiotics. Importantly, also the only need for admission to the hospital was associated with a higher rate of antibiotic prescription. To our knowledge, this is the first multinational study assessing the use of antibiotics in children with COVID-19 and MIS-C, therefore pediatric studies to compare our findings are not available. Velasco-Arnaiz et al (11) are the only authors that evaluated antibiotic use in a pediatric referral center before and during the pandemic. The use of azithromycin, initially considered as first-line therapy in severe COVID-19 patients in combination with hydroxychloroquine, increased, particularly in PICU setting. The use of ceftriaxone and teicoplanin, doubled in the PICU in April 2020 compared with April 2019. In non-PICU patients, piperacillin-tazobactam and ciprofloxacin use increased. Other antibiotics for community-acquired infections were prescribed less than in the same period in 2019, and cefazolin use decreased due to the dramatic drop in the number of surgeries. Also in our cohort, cephalosporins were frequently prescribed, while, interestingly,

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

macrolides represented only 9.2% of all prescriptions. This is probably because the peak of pediatric cases in Latin America was registered when the concept of utility of azythromicine in COVID-19 was weaker. Confirmed or suspected sepsis was the main reason for antibiotic prescription. This was an expected finding, since the pathogenesis (13) and clinical presentation of MIS-C overlap with those of sepsis, and there is general consensus for starting broad-spectrum antibiotics in these children (9). However, MIS-C children represented only 7.0% of the entire cohort, while 24.5% of children received antibiotics. These data suggest a potential overuse of empirical antibiotics in COVID-19 children. Considering that COVID-19 is often a milder disease in children compared with adults (14), the pediatric community is expected to empirically use antibiotics less frequently. However, the rate of prescriptions we detected is not widely different from those reported in adult studies. In fact, in our study, the need for hospital admission was independently associated with a higher probability of receiving antibiotic (OR 6.87, 95% CI 4.34-10.89). Addressing adult studies, Seatone et al reported that 38.3% of COVID-19 patients were prescribed antibiotics. Antibiotic prevalence was 45.0%, and 73.9% were prescribed for suspected respiratory tract infection. Amoxicillin, doxycycline and co-amoxiclay accounted for over half of all antibiotics in non-critical care wards, and meropenem, piperacillin-tazobactam and co-amoxiclav accounted for approximately half prescribed in critical care (15). Although there are no data on bacterial co-infections in children with COVID-19 that may inform better policies of pediatric antimicrobial stewardships during the pandemic, even in adults, where COVID-19 is having a much more severe impact, the burden of bacterial co-infections seems to be relatively low in most published studies (16-23). Buehrle et al found bacterial infections in 31% (5/16) of COVID-19 patients, while antibiotics were administered to 56% (9/16) of patients during hospitalization, but 100% (9/9) of patients requiring ICU care (16). In Spain, Garcia-Vidal et al (17) found that 31/989 (3%) COVID-19 adults presented with community-acquired co-infections,

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

mainly Streptococcus pneumoniae and Staphylococcus aureus pneumonia. Hospital-acquired infection was diagnosed in 43/989 patients (4%), with 25/44 (57%) occurring in critical care (mainly Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., and Staphylococcus aureus). Coagulase-negative staphylococci were the most common organisms causing documented bloodstream infection (7/16; 44%). Low observed rates of bacterial and fungal infection in COVID-19 patients have also been reported from the UK, where Hughes identified bacterial infection in 51/ 836 COVID-19 patients (6%) (18, 19). A review of eighteen full texts showed that 62/806 (8%) COVID-19 patients experienced bacterial/fungal co-infection during hospital admission, while on secondary analysis, 1450/2010 (72%) of patients were found to have received antimicrobial therapy (20). One Italian study even saw a reduction in Clostridioides difficile infections in hospitalized patients (21). In a rapid review, Fattorini et al found that only 1.3% of 522 COVID-19 patients in intensive care units, and apparently no COVID19 patients in other units, developed a healthcareassociated super-infection with antimicrobial-resistant bacteria (22, 23). In our study, having signs or symptoms suggestive of lower respiratory tract infections, without radiologic evidence of pneumonia/ARDS, was associated with a lower probability of receiving antibiotics. This finding may be explained by the fact that in pediatrics such presentations are usually suggestive of a clinical diagnosis of bronchiolitis, wheezing or asthma, conditions that do not require routine antibiotic administration. Our study clearly shows a high variability of reasons for antibiotic prescriptions and regimens chosen, as well as a significant variability among different centers. These findings highlight the uncertainties that physicians daily face in the management of COVID-19 patients. While the World Health Organization currently recommends against the prescribing of antimicrobials in mild to moderate COVID-19 cases without clear indication of bacterial infection (24), the difficulty in differentiating COVID-19 from bacterial infections on initial presentation challenges clinicians and antimicrobial stewardship practices (25). Almost after one year of the pandemic, there is no

evidence to support decision-making on bacterial infection and antimicrobial stewardship in the context of COVID-19 (19), particularly in children. This uncertainty is likely to drive unnecessary antimicrobial prescribing in COVID-19 children who are unlikely, according to adult evidences, to benefit from empiric antibiotic prescriptions. This scenario will potentially increase the selection of drug resistant infections (26) and will make patients more vulnerable to bacterial infections, even during future viral pandemics that may favor bacterial co-infections from drug resistant bugs (27). Our study has some limitations to address. We did not collect bacteria isolation and antibiotic sensitivities throughout the pandemic in the participating centers. Blood results, including inflammatory markers, were not collected. In addition, an independent expert did not assess the appropriateness of antibiotic prescription, nor the length of administration. Last, the reason for starting antibiotic was subjectively based on the evaluating clinician. The main reason for this approach was that Latin American clinicians are still struggling in the front-line, with hospitals having limited human resources to dedicate extra time for clinical research. Despite these limitations, this study provides the largest overview of antibiotic use in children with COVID-19 and MIS-C to date. In conclusion, our study showed a relatively high rate of antibiotic prescriptions in children with COVID-19 and in particular in those with severe disease or MIS-C. Importantly, we found a significant variation in reasons for prescriptions of antibiotics and type of chosen therapies, as well in hospital practices, highlighting current uncertainties and lack of guidelines for the recognition of bacterial infections in COVID-19 children. Prospective studies are urgently needed to provide better evidence on the recognition and management of bacterial infections in COVID-19 children, as well as to develop dedicated antimicrobial stewardship programs.

ACKNOWLEDGMENTS

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

We are grateful to all collaborators that helped the development of the DOMINGO study group.

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

References 1- Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020 Jun;145(6):e20200702. doi: 10.1542/peds.2020-0702. 2- Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI, Gabrovska N, Velizarova S, Prunk P, Osterman V, Krivec U, Lo Vecchio A, Shingadia D, Soriano-Arandes A, Melendo S, Lanari M, Pierantoni L, Wagner N, L'Huillier AG, Heininger U, Ritz N, Bandi S, Krajcar N, Roglić S, Santos M, Christiaens C, Creuven M, Buonsenso D, Welch SB, Bogyi M, Brinkmann F, Tebruegge M; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Sep;4(9):653-661. doi: 10.1016/S2352-4642(20)30177-2. 3- Parri N, Lenge M, Cantoni B, Arrighini A, Romanengo M, Urbino A, Da Dalt L, Verdoni L, Giacchero R, Lanari M, Musolino AM, Biban P, La Fauci G, Pilotto C, Buonsenso D, Chiossi M, Agostiniani R, Plebani A, Zampogna S, Barbieri MA, De Masi S, Agostoni C, Masi S; CONFIDENCE RESEARCH GROUP. COVID-19 in 17 Italian Pediatric Emergency Departments. Pediatrics. 2020 Sep 23:e20201235. doi: 10.1542/peds.2020-1235. 4- Bailey LC, Razzaghi H, Burrows EK, Bunnell HT, Camacho PEF, Christakis DA, Eckrich D, Kitzmiller M, Lin SM, Magnusen BC, Newland J, Pajor NM, Ranade D, Rao S, Sofela O, Zahner J, Respiratory Syndrome Coronavirus 2 Across the United States. JAMA Pediatr. 2020 Nov 23. doi: 10.1001/jamapediatrics.2020.5052. 5- Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga M, Salcedo-Lozada P, Melchior P, de Oliveira RB, Tirado Caballero JC, Redondo HP, Montes Fontalvo LV, Hernandez R, Chavez C, Campos F, Uribe F, Del Aguila O, Rios Aida JA, Buitrago AP, Betancur Londoño LM, Mendoza Vega LF, Hernández CA, Sali M, Higuita Palacio JE, Gomez-Vargas J, Yock-Corrales A, Buonsenso D. COVID-19 and Multisystem Inflammatory Syndrome in 346 Latin American Children: A Multinational Study. Pediatr Infect Dis J. 2020 Oct 12. doi: 347 10.1097/INF.0000000000002949. 348 6- Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse A, Miller 349 O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A, Shimizu C, Herberg J, 350 Burns JC, Lyall H, Levin M; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. 351 Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020 Jul 21;324(3):259-269. doi: 352 353 10.1001/jama.2020.10369. 354 7- Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the 355 Antiviral Activity of Azithromycin and Use in COVID-19. Clin Pharmacol Ther. 2020 356 Aug;108(2):201-211. doi: 10.1002/cpt.1857. 357 8- Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, 358 Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, 359 Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, 360 Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, 361 Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, 362 Machado FR, Berwanger O; Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or 363 without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Nov 19;383(21):2041-364 2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23. Erratum in: N Engl J Med. 2020 Nov 365 19:383(21):e119. 366 9- Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, Kaleem M, Tulloh R, Peters MJ, Almond S, Davis PJ, Levin M, Tometzki A, Faust SN, Knight M, Kenny S; PIMS-TS 367 368 National Consensus Management Study Group. A national consensus management pathway for 369 paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): 370 results of a national Delphi process. Lancet Child Adolesc Health. 2020 Sep 18:S2352-371 4642(20)30304-7. doi: 10.1016/S2352-4642(20)30304-7. 372 10- Buehrle DJ, Decker BK, Wagener MM, Adalja A, Singh N, McEllistrem MC, Nguyen MH, Clancy 373 CJ. Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 374 Epicenter. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01011-20. doi: 375 10.1128/AAC.01011-20. 376 11- Velasco-Arnaiz E, López-Ramos MG, Simó-Nebot S, Jordan I, Ríos-Barnés M, Urrea-Ayala M, 377 Monsonís M, Fortuny C, Noguera-Julian A; Kids Corona project. Pediatric antimicrobial 378 stewardship in the COVID-19 outbreak. Infect Control Hosp Epidemiol. 2020 Jun 24:1-3. doi: 379 10.1017/ice.2020.312. Epub ahead of print. 380 12- Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Sárachaga 381 M, Salcedo-Lozada P, Sunohara RA, Melchior P, Del Razo JOF, Tirado-Caballero JC, Tasayco-382 Muñoz JA, Pinzon-Redondo H, Montes-Fontalvo LV, Ochoa T, Eduardo Campos F, Hernandez R, 383 Limansky L, Del Aguila O, Buonsenso D. COVID-19 in South American Children: A Call For 384 Action. Pediatr Infect Dis J. 2020 Oct;39(10):e332-e334. doi: 10.1097/INF.0000000000002851. 385 13- Buonsenso D, Riitano F, Valentini P. Pediatric Inflammatory Multisystem Syndrome Temporally 386 Related With SARS-CoV-2: Immunological Similarities With Acute Rheumatic Fever and Toxic 387 Shock Syndrome. Front Pediatr. 2020 Sep 11;8:574. doi: 10.3389/fped.2020.00574. 388 14- Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 389 390 Sep 2020;doi:10.1001/jamapediatrics.2020.4573 391 15- Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, Griffith D, Jeffreys D, 392 Hamilton K, Choo-Kang B, Brittain S, Guthrie D, Sneddon J. Survey of antibiotic and antifungal 393 prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020 394 Sep 26:S0163-4453(20)30616-2. doi: 10.1016/j.jinf.2020.09.024. 395 16- Buehrle DJ, Decker BK, Wagener MM, Adalja A, Singh N, McEllistrem MC, Nguyen MH, Clancy 396 CJ. Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease Epicenter. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01011-20. doi: 397 398 10.1128/AAC.01011-20. 399 17- Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, 400 Fernandez-Pittol M, Pitart C, Inciarte A, Bodro M, Morata L, Ambrosioni J, Grafia I, Meira F, Macaya I, Cardozo C, Casals C, Tellez A, Castro P, Marco F, García F, Mensa J, Martínez JA, 401

402 Soriano A; COVID-19 Researchers Group. Incidence of co-infections and superinfections in 403 hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2020 Jul 404 31:S1198-743X(20)30450-X. doi: 10.1016/j.cmi.2020.07.041. 405 18- Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among 406 hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. 407 Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. 408 19- Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in 409 COVID-19. Clin Microbiol Infect. 2020 Oct 9:S1198-743X(20)30577-2. doi: 410 10.1016/j.cmi.2020.09.025. 411 20- Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, 412 Holmes A. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to 413 support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020 May 2:ciaa530. doi: 414 10.1093/cid/ciaa530. 415 21- Bentivegna E, Alessio G, Spuntarelli V, Luciani M, Santino I, Simmaco M, et al. Impact of COVID-416 19 prevention measures on risk of health care-associated Clostridium difficile infection. Am J Infect 417 Control. 2020 Oct 5;S0196-6553(20)30891-9. https://doi.org/10.1016/j.ajic.2020.09.010 418 22- Fattorini L, Creti R, Palma C, Pantosti A, Unit of Antibiotic Resistance and Special Pathogens, Unit 419 of Antibiotic Resistance and Special Pathogens of the Department of Infectious Diseases, Istituto 420 Superiore di Sanità, Rome. Bacterial coinfections in COVID-19: an underestimated adversary. Ann 421 Ist Super Sanita. 2020;56(3):359-64. https://doi.org/10.4415/ANN 20 03 14 422 23- Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial 423 10.2807/1560resistance? Euro Surveill. 2020 Nov;25(45):2001886. doi: 424 7917.ES.2020.25.45.2001886. 425 24- World Health Organization. Clinical management of COVID-19. 2020. 426 https://www.who.int/publications/i/item/clinical-management-of-covid-19. 427 25- Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial 428 stewardship principles! Clin Microbiol Infect 2020;26: 808e10.

https://doi.org/10.1016/j.cmi.2020.04.024.

26- Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2016;387:176e87. https://doi.org/10.1016/S0140-6736(15)00473-0.

27- Vaillancourt M, Jorth P. The Unrecognized Threat of Secondary Bacterial Infections with COVID-19. mBio. 2020 Aug 7;11(4):e01806-20. doi: 10.1128/mBio.01806-20.

Characteristic n % Female sex 484 48.9 Age group 202 20.4 0 y 202 20.4 1-2 y 229 23.1 3-5 y 144 14.5 6-11 y 247 24.9 12-17 y 168 17.0 COVID-19 confirmed by real-time PCR 639 64.5 Positive SARS-CoV-2 IgG 352 35.6 Delay between onset and diagnosis 352 35.6 Delay between onset and diagnosis 437 44.1 2-7 d 460 46.5 >7 d 93 9.4 Likely index case 281 28.4 Parent 281 28.4 Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the			
Age group 0 y 202 20.4 1-2 y 229 23.1 3-5 y 144 14.5 6-11 y 247 24.9 12-17 y 168 17.0 COVID-19 confirmed by real-time PCR 639 64.5 Positive SARS-CoV-2 IgG 352 35.6 Delay between onset and diagnosis 352 35.6 Delay between onset and diagnosis 437 44.1 2-7 d 460 46.5 >7.7 7 d 93 9.4 Likely index case Parent 281 28.4 Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7	Characteristic	n	%
0 y 202 20.4 1-2 y 229 23.1 3-5 y 144 14.5 6-11 y 247 24.9 12-17 y 168 17.0 COVID-19 confirmed by real-time PCR 639 64.5 Positive SARS-CoV-2 IgG 352 35.6 Delay between onset and diagnosis 0-1 d 437 44.1 2-7 d 460 46.5 >77 d 93 9.4 Likely index case Parent 281 28.4 Sibling 14 1.4 0ther 120 12.1 120 12.1 120 12.1 14 1.4 0ther 120 12.1 12.9 11.1 11.1 11.1 11.1 11.1 12.9 <t< td=""><td>Female sex</td><td>484</td><td>48.9</td></t<>	Female sex	484	48.9
	Age group		
3–5 y 6–11 y 247 24.9 12–17 y 168 17.0 COVID-19 confirmed by real-time PCR 639 64.5 Positive SARS-CoV-2 IgG 352 35.6 Delay between onset and diagnosis 0–1 d 2–7 d 460 465 > 7 d 93 9.4 Likely index case Parent Sibling 14 0ther 120 12.1 Unknown 575 58.1 Medical history Known history of BCG vaccine Pre-existing medical conditions 128 129 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency Robert Hast 6 months 8 0.8 Admitted to the hospital Intensive care during hospital stay Symptoms Pyrexia (≥38.0/≥100.4 °C/°F) Upper respiratory tract infection Diarrhea and/or vomiting Lower respiratory tract infection Diarrhea and/or vomiting Lower respiratory tract infection Positive (pneumonia* and/or ARDS†)	0 y	202	20.4
6-11 y 12-17 y 168 17.0 12-17 y 168 17.0 COVID-19 confirmed by real-time PCR 639 64.5 Positive SARS-CoV-2 IgG 352 35.6 Delay between onset and diagnosis	1–2 y	229	23.1
6-11 y 12-17 y 168 17.0 12-17 y 168 17.0 COVID-19 confirmed by real-time PCR 639 64.5 Positive SARS-CoV-2 IgG 352 35.6 Delay between onset and diagnosis	3–5 y	144	14.5
COVID-19 confirmed by real-time PCR Positive SARS-CoV-2 IgG 352 35.6 Delay between onset and diagnosis 0-1 d 2-7 d 460 46.5 >7 d 93 9.4 Likely index case Parent Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Known history of BCG vaccine Pre-existing medical conditions Inmunosuppressants at the time of diagnosis 11 Primary or secondary immunodeficiency Chemotherapy over the last 6 months Admitted to the hospital Intensive care during hospital stay Pyrexia (≥38.0/≥100.4 °C/°F) Upper respiratory tract infection Diarrhea and/or vomiting Lower respiratory tract infection Positive (pneumonia* and/or ARDS†) Positive (pneumonia* and/or ARDS†) P3 Respiratory support Oxygen support 117 11.8		247	24.9
Positive SARS-CoV-2 IgG Delay between onset and diagnosis 0−1 d 2−7 d 460 46.5 > 7 d 93 9.4 Likely index case Parent Parent Sibling 14 1.4 Other 120 12.1 Unknown 120 121 Unknown 121 Unknown 122 Unknown 123 124 Unknown 124 125 127 Unknown 125 121 127 Unknown 125 127 Unknown 126 127 Unknown 128 128 129 129 129 120 120 121 121 121 121 121 122 122 123 123 124 124 125 127 126 126 127 126 128 127 128 128 129 129 129 129 129 129 129 129 129 129	12–17 y	168	17.0
Positive SARS-CoV-2 IgG Delay between onset and diagnosis 0−1 d 2−7 d 460 46.5 > 7 d 93 9.4 Likely index case Parent Parent Sibling 14 1.4 Other 120 12.1 Unknown 120 121 Unknown 121 Unknown 122 Unknown 123 124 Unknown 124 125 127 Unknown 125 121 127 Unknown 125 127 Unknown 126 127 Unknown 128 128 129 129 129 120 120 121 121 121 121 121 122 122 123 123 124 124 125 127 126 126 127 126 128 127 128 128 129 129 129 129 129 129 129 129 129 129	COVID-19 confirmed by real-time PCR	639	64.5
0-1 d 437 44.1 2-7 d 460 46.5 >7 d 93 9.4 Likely index case Parent 281 28.4 Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Chemotherapy over the last 6 months 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 117 11.8		352	35.6
2–7 d 460 46.5 >7 d 93 9.4 Likely index case Parent 281 28.4 Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Chemotherapy over the last 6 months 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7 Symptoms Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 117 11.8 Likely 194 46.5 281 28.4 29.4 29.4 20.8 20.8	Delay between onset and diagnosis		
S7 d	0–1 d	437	44.1
Likely index case Parent 281 28.4 Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Total conditions 128 Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Chemotherapy over the last 6 months 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7 Symptoms Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 <td>2–7 d</td> <td>460</td> <td>46.5</td>	2–7 d	460	46.5
Parent 281 28.4 Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Total conditions 128 Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Chemotherapy over the last 6 months 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7 Symptoms Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support	>7 d	93	9.4
Sibling 14 1.4 Other 120 12.1 Unknown 575 58.1 Medical history Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Chemotherapy over the last 6 months 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7 Symptoms Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 0xygen support 117 11.8	Likely index case		
Other Unknown12012.1Unknown57558.1Medical history \times \times Known history of BCG vaccine74074.7Pre-existing medical conditions12812.9Immunosuppressants at the time of diagnosis111.1Primary or secondary immunodeficiency80.8Chemotherapy over the last 6 months80.8Admitted to the hospital30330.6Intensive care during hospital stay474.7Symptoms \times \times \times Pyrexia (≥38.0/≥100.4 °C/°F)67768.4Upper respiratory tract infection46647.1Diarrhea and/or vomiting30130.4Lower respiratory tract infection21521.7Headache10410.5Chest X-ray \times 10410.5Chest X-ray \times 19319.5Positive (pneumonia* and/or ARDS†)929.3Respiratory support \times 11711.8	Parent	281	28.4
Unknown 575 58.1 Medical history 740 74.7 Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Chemotherapy over the last 6 months 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7 Symptoms 8 6.8.4 Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 0xygen support 117 11.8	Sibling	14	1.4
Medical historyKnown history of BCG vaccine74074.7Pre-existing medical conditions12812.9Immunosuppressants at the time of diagnosis111.1Primary or secondary immunodeficiency80.8Chemotherapy over the last 6 months80.8Admitted to the hospital30330.6Intensive care during hospital stay474.7Symptoms847Pyrexia (≥38.0/≥100.4 °C/°F)67768.4Upper respiratory tract infection46647.1Diarrhea and/or vomiting30130.4Lower respiratory tract infection21521.7Headache10410.5Chest X-ray10410.5Not performed70571.2Negative19319.5Positive (pneumonia* and/or ARDS†)929.3Respiratory support0xygen support11711.8	Other	120	12.1
Known history of BCG vaccine 740 74.7 Pre-existing medical conditions 128 12.9 Immunosuppressants at the time of diagnosis 11 1.1 Primary or secondary immunodeficiency 8 0.8 Chemotherapy over the last 6 months 8 0.8 Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7 Symptoms Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support Oxygen support 117 11.8	Unknown	575	58.1
Pre-existing medical conditions Immunosuppressants at the time of diagnosis Inmunosuppressants at the time of diagnosis Primary or secondary immunodeficiency Remotherapy over the last 6 months Remotherapy over the last 6 mon	Medical history		
Immunosuppressants at the time of diagnosis111.1Primary or secondary immunodeficiency80.8Chemotherapy over the last 6 months80.8Admitted to the hospital30330.6Intensive care during hospital stay474.7Symptoms	Known history of BCG vaccine	740	74.7
Primary or secondary immunodeficiency80.8Chemotherapy over the last 6 months80.8Admitted to the hospital30330.6Intensive care during hospital stay474.7Symptoms***47Pyrexia (≥38.0/≥100.4 °C/°F)67768.4Upper respiratory tract infection46647.1Diarrhea and/or vomiting30130.4Lower respiratory tract infection21521.7Headache10410.5Chest X-ray***19319.5Not performed70571.271.2Negative19319.5Positive (pneumonia* and/or ARDS†)929.3Respiratory supportOxygen support11711.8	Pre-existing medical conditions	128	12.9
Chemotherapy over the last 6 months80.8Admitted to the hospital30330.6Intensive care during hospital stay474.7Symptoms 47 4.7Pyrexia (≥38.0/≥100.4 °C/°F)67768.4Upper respiratory tract infection46647.1Diarrhea and/or vomiting30130.4Lower respiratory tract infection21521.7Headache10410.5Chest X-ray 104 10.5Not performed70571.2Negative19319.5Positive (pneumonia* and/or ARDS†)929.3Respiratory support 117 11.8	Immunosuppressants at the time of diagnosis	11	1.1
Admitted to the hospital 303 30.6 Intensive care during hospital stay 47 4.7 Symptoms	Primary or secondary immunodeficiency	8	0.8
Intensive care during hospital stay474.7Symptoms474.7Pyrexia (≥38.0/≥100.4 °C/°F)67768.4Upper respiratory tract infection46647.1Diarrhea and/or vomiting30130.4Lower respiratory tract infection21521.7Headache10410.5Chest X-rayValue105Not performed70571.2Negative19319.5Positive (pneumonia* and/or ARDS†)929.3Respiratory support0xygen support11711.8	Chemotherapy over the last 6 months	8	0.8
SymptomsPyrexia (≥38.0/≥100.4 °C/°F)67768.4Upper respiratory tract infection46647.1Diarrhea and/or vomiting30130.4Lower respiratory tract infection21521.7Headache10410.5Chest X-ray $\frac{1}{1}$ $\frac{1}{1}$ Not performed70571.2Negative19319.5Positive (pneumonia* and/or ARDS†)929.3Respiratory support $\frac{1}{1}$ 11.8	Admitted to the hospital	303	30.6
Pyrexia (≥38.0/≥100.4 °C/°F) 677 68.4 Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 0xygen support 117 11.8	Intensive care during hospital stay	47	4.7
Upper respiratory tract infection 466 47.1 Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray Value 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 0xygen support 117 11.8	Symptoms		
Diarrhea and/or vomiting 301 30.4 Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 0xygen support 117 11.8	Pyrexia (≥38.0/≥100.4 °C/°F)	677	68.4
Lower respiratory tract infection 215 21.7 Headache 104 10.5 Chest X-ray 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 30 30 Oxygen support 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31 11 31 31	Upper respiratory tract infection	466	47.1
Headache 104 10.5 Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support Oxygen support 117 11.8	Diarrhea and/or vomiting	301	30.4
Chest X-ray Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support Oxygen support 117 11.8	Lower respiratory tract infection	215	21.7
Not performed 705 71.2 Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support Oxygen support 117 11.8	Headache	104	10.5
Negative 193 19.5 Positive (pneumonia* and/or ARDS†) 92 9.3 Respiratory support 117 11.8	Chest X-ray		
Positive (pneumonia* and/or ARDS†) Respiratory support Oxygen support 117 11.8	Not performed	705	71.2
Respiratory support Oxygen support 117 11.8	Negative	193	19.5
Oxygen support 117 11.8	Positive (pneumonia* and/or ARDS†)	92	9.3
	Respiratory support		
	Oxygen support	117	11.8
Mechanical ventilation 31 3.1	Mechanical ventilation	31	3.1

Continuous positive airway pressure (CPAP)	11	1.1
Extracorporeal membrane oxygenation (ECMO)	0	0.0
Administration of inotropes	29	2.9
Co-infections detected in respiratory samples(s)‡	14	1.4
Drug administration		
Systemic corticosteroids	90	9.1
Intravenous immunoglobulin (IVIG)	60	6.1
Hydroxychloroquine	9	0.9
Oseltamivir	8	0.8
Lopinavir or ritonavir	3	0.3
Non-corticosteroid immunosuppressants	3	0.3
Favipiravir	2	0.2
Remdesivir	2	0.2
Chloroquine, ribavirin or zanamivir	0	0.0
MIS-C diagnosis		
No	921	93.0
Yes, with no cardiac or joint involvement	33	3.3
Yes, with cardiac involvement§	23	2.3
Yes, with joint involvement	11	1.1
Yes, with cardiac and joint involvement§	2	0.2
Tocilizumab administration to treat MIS-C	8	0.8
Current status		
All symptoms resolved	969	97.9
Dead¶	8	0.8
Still symptomatic	7	0.7
Long-term sequelae	6	0.6
Center		
Peru	383	38.7
Costa Rica	299	30.2
Argentina	253	25.6
Colombia	43	4.3
Mexico	12	1.2

Table 1. Characteristics of the study sample (n = 990).

- †3 cases of interstitial disease, 3 cases of consolidation and 10 unspecified diagnoses.
- ‡8 mycoplasmas, 3 rhinoviruses, 1 cytomegalovirus, 1 Epstein–Barr virus and 1 unspecified virus.
- \$10 cases of pericardial effusion, 6 cases of coronary dilatation, 5 cases of myocarditis and 4 cases of "other" cardiac involvement.
- ¶Mean time from symptom onset to death was 14 ± 8 days, ranging from 3 to 27.
- 445 COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; SARS-CoV-2, Severe acute
- respiratory syndrome coronavirus 2; *IgG*, immunoglobulin G; *BCG*, bacillus Calmette–Guérin; *ARDS*, Acute respiratory distress syndrome; MIS-C, multisystem inflammatory syndrome.

^{*45} cases of interstitial disease, 30 cases of consolidation, 4 cases of pleural effusion and 13 unspecified diagnoses.

	Odds	Odds ratio P-value	95% confidence interval	
Characteristic			Lower bound	Upper bound
Sex				11
Male	Ref.			
Female	1.50	0.040	1.02	2.21
Age group				
0 y	Ref.			
1–2 y	0.63	0.118	0.35	1.13
3–5 y	0.82	0.556	0.43	1.58
6–11 y	1.13	0.670	0.65	1.98
12–17 y	0.92	0.821	0.47	1.82
Immunosuppressants, immunodeficiency or chemo				
No	Ref.			
Yes	1.65	0.451	0.45	6.05
Hospitalization				
No	Ref.			
Yes, without intensive care	6.87	< 0.001	4.34	10.89
Yes, with intensive care	9.60	< 0.001	2.77	33.27
Pyrexia (≥38.0/≥100.4 °C/°F)				
No	Ref.			
Yes	1.84	0.011	1.15	2.96
Upper respiratory tract infection				
No	Ref.			
Yes	1.08	0.730	0.71	1.65
Diarrhea and/or vomiting				
No	Ref.			
Yes	1.05	0.822	0.67	1.64
Lower respiratory tract infection				
No	Ref.			
Yes	0.34	0.007	0.16	0.74
Headache				
No	Ref.			
Yes	0.88	0.746	0.42	1.87
Chest X-ray abnormalities (pneumonia and/or ARDS)				
No	Ref.			
Yes	4.40	< 0.001	1.99	9.71
Oxygen support, mechanical ventilation and/or CPAP				
No	Ref.			
Yes	2.21	0.050	1.002	4.88
Administration of systemic corticosteroids				
No	Ref.			
Yes	4.39	< 0.001	2.01	9.58
MIS-C diagnosis				
No	Ref.			
Yes, w/o cardiac involvement	10.35	0.050	1.005	>100
Yes, w/ cardiac involvement	45.48	0.011	2.44	>100
Center				
Hospital San Bartolomé (PE)	Ref.	0.004	0.24	0.04
Hospital Nacional de Niños (CR)	0.58	0.034	0.34	0.96
Hospital Isidoro Iriarte (AR)	0.25	< 0.001	0.14	0.46
Hospital Edgardo Rebagliati Martins (PE)	0.04	0.014	0.00	0.53
Hospital Pablo Tobón Uribe (CO)	0.05	< 0.001	0.01	0.25
Clínica Jasmédica (PE)	1.48	0.466	0.51	4.28
Hospital General Regional 200 Tecámac (MX)	12.24	0.045	1.06	>100

Table 2. Multivariable logistic regression analysis of antibiotics use (n = 990).

FIGURES

450

451

Figure 1. Reasons for antibiotic use (n = 243).





Figure 2. Classes of antibiotics administered to the patients, alone or in combination (n = 243).



Notes: cephalosporines include cefalexine, cefalotin, cefepime, cefotaxime, ceftazidime and ceftriaxone; aminoglycosides include amikacin and gentamicin; penicillins include amoxicillin and ampicillin; antianaerobic drugs include metronidazole; macrolides include azithromycin and clarithromycin; antistaphylococcal drugs include clindamycin, trimethoprim and vancomycin; carbapenems includemeropenem; others include various combinations of these antibiotics as well as fluoroquinolones (ciprofloxacin).




Figure 3.Prevalence of antibiotic use between April and October 2020.

Notes: Linear trend was assessed using a linear regression model with variance-weighted least squares.